AntibioticDB

Highest development stage: Phase 2

Development active

Gram-positive activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Inhibits FabI, which determins the completing of each cycle of elongation in the fatty acid synthesis. Active against Staphylococcus only.

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10755

Source: https://www.debiopharm.com/debiopharm-international/pipeline/debio1450-bone-joint-infections/

Citation (1): http://aac.asm.org/content/59/5/2583.long

Citation (2): https://www.debiopharm.com/our-business/pipeline/item/3548-debiopharm-international-sa-initiates-clinical-phase-ii-study-evaluating-debio-1450-in-staphylococcal-skin-infections.html

Citation (3): https://www.ncbi.nlm.nih.gov/pubmed/25691627

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/10407120

Afabicin dephosphono, Debio 1452/Debio1452, AFN-1252

Fatty acid synthesis inhibitor (FabI inhibitor)

Debiopharm Group, Switzerland

2014